# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Mizuho analyst Graig Suvannavejh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $36 to $82.
Stifel analyst Stephen Willey maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $67 to $74.
Stifel analyst Stephen Willey maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $39 to $67.
TD Cowen analyst Ritu Baral maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $45 to $67.
UBS analyst Trung Huynh maintains Insmed (NASDAQ:INSM) with a Buy and raises the price target from $46 to $58.